Effects of switching from olanzapine to aripiprazole on the metabolic profiles of patients with schizophrenia and metabolic syndrome: a double-blind, randomized, open-label study
Rayees Ahmad Wani, Mansoor Ahmad Dar, Rajesh Kumar Chandel, Yasir Hassan Rather, Inaamul Haq, Arshad Hussain, Altaf Ahmad MallaDepartment of Psychiatry, Government Medical College, Srinagar, Jammu and Kashmir, IndiaBackground: Patients with schizophrenia suffer high rates of metabolic derangements...
Enregistré dans:
Auteurs principaux: | Wani RA, Dar MA, Chandel RK, Rather YH, Haq I, Hussain A, Malla AA |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2015
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/682f7f59e2684a8184f17a04ae3bb4af |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Effects of switching from olanzapine to aripiprazole on the metabolic profiles of patients with schizophrenia and metabolic syndrome: a double-blind, randomized, open-label study [Corrigendum]
par: Wani RA, et autres
Publié: (2015) -
An economic evaluation of aripiprazole vs olanzapine adapted to the Italian setting using outcomes of metabolic syndrome and risk for diabetes in patients with schizophrenia
par: Giorgio L Colombo, et autres
Publié: (2008) -
Gabapentin adjunctive to risperidone or olanzapine in partially responsive schizophrenia: an open-label pilot study
par: Adel Gabriel
Publié: (2010) -
Erratum: An economic evaluation of aripiprazole vs olanzapine adapted to the Italian setting using outcomes of metabolic syndrome and risk for diabetes in patients with schizophrenia. Neuropsychiatr Dis Treat, 4: 967–976
par: Colombo GL, et autres
Publié: (2009) -
A Review of Switching Strategies for Patients with Schizophrenia Comorbid with Metabolic Syndrome or Metabolic Abnormalities
par: Liao X, et autres
Publié: (2021)